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Abstract
Background: Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer deaths
among women worldwide. The use of mobile mammography units to offer screening to women living in remote
areas is a rational strategy to increase the number of women examined. This study aimed to evaluate results from
the first 2 years of a government-organized mammography screening program implemented with a mobile unit
(MU) and a fixed unit (FU) in a rural county in Brazil. The program offered breast cancer screening to women living
in Barretos and the surrounding area.
Methods: Based on epidemiologic data, 54 238 women, aged 40 to 69 years, were eligible for breast cancer
screening. The study included women examined from April 1, 2003 to March 31, 2005. The chi-square test and
Bonferroni correction analyses were used to evaluate the frequencies of tumors and the importance of clinical
parameters and tumor characteristics. Significance was set at p < 0.05.
Results: Overall, 17 964 women underwent mammography. This represented 33.1% of eligible women in the area.
A mean of 18.6 and 26.3 women per day were examined in the FU and MU, respectively. Seventy six patients were
diagnosed with breast cancer (41 (54%) in the MU). This represented 4.2 cases of breast cancer per 1000
examinations. The number of cancers detected was significantly higher in women aged 60 to 69 years than in
those aged 50 to 59 years (p < 0.001) or 40 to 49 years (p < 0.001). No difference was observed between women
aged 40 to 49 years and those aged 50 to 59 years (p = 0.164). The proportion of tumors in the early (EC 0 and EC
I) and advanced (CS III and CS IV) stages of development were 43.4% and 15.8%, respectively.
Conclusions: Preliminary results indicate that this mammography screening program is feasible for implementation
in a rural Brazilian territory and favor program continuation.
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Background
Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer deaths among women in
both economically developed and developing countries
[1]. In 2008, an estimated 1 384 155 cases of breast cancer
occurred worldwide, and 458 503 women died from the
disease [2]. According to the Brazilian National Institute
of Cancer (INCA), 49 240 new cases were expected in
the year 2011 [3]. North America, Australia, and some
European countries have the highest annual indexes of
new cases. The global 5-year survival rates are 73% in
developed countries and 57% in developing countries [4].
Breast cancer screening with mammography has proven
to be effective in reducing BC mortality in a number of
studies, and thus mammography screening has become
the standard option worldwide for early detection of
tumors [5,6]. Some programs have produced reports of
the effective and beneficial use of mobile units (MU) as
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well as fixed units (FU) for screening, according to specific
organizational and geographic situations [7,8].
In regions with easy access to mammography, screen-
ing may be conducted in an organized or an opportunis-
tic manner [9]. In opportunistic screening, invitations to
screening are passive; here, the individual must decide to
undergo screening or they may contact health care pro-
viders that offer screening. Thus, opportunistic screening
lacks some important requirements for effectiveness, in-
cluding eligibility parameters, quality assurance of the
technical proceedings, follow-up of positive test results,
and program evaluation [9]. Most notably, opportunistic
screening lacks the population perspective, i.e., the pro-
per setting and organization that is needed to fulfill the
aim of mortality reduction in the general population. In
contrast, an organized screening program permits re-
cruitment of women in target groups that are difficult to
reach, promotes increased return attendance, may de-
crease health care system costs, and includes routine on-
going quality assurance, evaluation, and overall program
monitoring [10]. Organized screening of the general po-
pulation can increase survival rates to 81% over 5 years
[4]. Nevertheless, low participation rates in breast cancer
screening remain a concern for many organized pro-
grams and have become the focus of intense research
[11]. The worldwide rate of participation in the first
round of an organized breast screening program ranged
from 10.6% in a territory of Canada [12] to 85–95% in
Finland [13].
In 2004, the Brazilian guidelines for breast cancer scree-
ning with mammography were introduced as a “recom-
mendation”. However, they were not part of a government
screening program [14]. Recent convincing evidence has
shown that organized screening can effectively reduce
breast cancer mortality [7,8,15]. This encouraged us to ini-
tiate a screening program in the remote Barretos region of
Brazil, and its neighboring areas.
The aim of this study was to evaluate the implementa-
tion process and the first 2 years of results from an or-
ganized program of breast cancer screening that was
introduced in the Barretos region of the state of São
Paulo; we also aimed to evaluate the potential impact on
public health strategy and cancer control in Brazil.
Methods
Participants
The breast cancer screening program was implemented
in the Barretos region, São Paulo, and 19 adjacent mu-
nicipalities. A description of the methodology has pre-
viously been published [16]. This study examined results
from the first round of the program, which included all
cases that had undergone mammography from April
2003 to March 2005 inclusive. The program targeted 54
238 eligible women, aged 40 to 69 years, living in rural
and urban areas. Exclusion criteria were a mammographic
screening within the previous 2 years and a previous his-
tory of breast cancer. The program was initially discussed
with community workers and social care assistants from
19 cities in the area. Regular meetings were convened to
clarify the goals and steps of the program. This study was
authorized by the institutional review board, process num-
ber 029/2006.
Screening units
We used 2 mammography units for screening: one MU
and one FU, which was located in the Department of Ima-
ging at the Barretos Cancer Hospital (BCH). Both units
had the same mammogram apparatus (Senograph™ 700 T,
GE Healthcare, Waukesha, WI, US), with one in the MU
and 3 in the FU. Each unit had a capacity for 40 mammo-
grams per day, allowing up to 40 examinations in the MU
and 120 examinations in the FU daily.
Classification report
Single-view mammography was used for the screening
and the Breast Imaging-Reporting and Data System
(BI-RADS) was used to classify findings in the mammo-
grams [17]. The BI-RADS 1 and BI-RADS 2 classifications
were considered a normal mammogram, and no further
action was taken. In these screening examinations, the
BI-RADS 3 classification was not considered to require
further exploration. In contrast, the BI-RADS 4 and
BI-RADS 5 classifications required referrals for further
examination. Women with carcinoma were treated at the
Barretos Cancer Hospital; operated women with no neo-
plastic lesions were followed according to hospital guide-
lines. The BCH´s protocol establishes that women with
breast changes detected by mammography but with a
negative biopsy must be followed up every 6 months for
2 years. If no changes are identified during this time, the
mammography is repeated annually.
Statistical analysis
Statistical analyses were performed using the the chi-
square test and Bonferroni correction test, with the level
of significance set at p < 0.05. Clinical and pathological
data were stored and analyzed with SPSS statistical soft-
ware (version 17.0, SPSS Inc., Chicago, IL, USA).
Consent
This project has been approved by the BCH´s Institutional
Review Board (process number 029/2006). Written
informed consent was obtained from the patient for publi-
cation of this report and any accompanying images.
Results
A total of 17 964 mammograms were performed during
the first round of the program; this included 33.1% of
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all women eligible for screening. Among these, 42.1%
(n = 7560) declared they had never had a mammogram
before. The average age was 51 years, with a median of
50 years. The MU accounted for 10 521 (58.6%) of the
examinations. The FU and MU averaged 18.6 and 26.3
examinations per day, respectively. The results were exa-
mined in the following age groups: 40–49 years (48.2%),
50–59 years (34.4%), and 60–69 years (17.4%) (Table 1).
Of the strategies used to motivate adherence to the
program, 46.8% of women declared that they were
convinced by community healthcare workers, 27.1% were
convinced by physicians, 12.4% were motivated by radio
announcements, 5.7% were motivated by conversations
with friends, and 8.1% were motivated by other reasons
(Table 1). A confirmatory examination was necessary for
9.4% (1690/17 964) of the women, and biopsies were
obtained from 2.63% (474/17 964). Seventy six cases of
breast cancer were identified: 41 (53.9%) of the cases were
examined in the MU and 35 (46.1%) in the FU. The posi-
tive predictive value (PPV) 1, or the percentage of abno-
rmal examinations that were consistent with cancer, was
4.49% (76/1690); the PPV 2, or the precise diagnosis based
on the biopsy, was 16% (76/474).
Of all cancers detected, based on histological analysis,
89.5% were invasive, and carcinoma in situ accounted for
the remaining 10.5%. Of the invasive cases, 80.9% were in-
vasive ductal carcinoma and 19.1% were lobular invasive
carcinomas (Table 2). The frequency of breast cancer in
this population was 4.2 cases per 1000 examinations. Can-
cer frequency was highest in the 60–69-year-old group,
with 6.7 cases/1000 examinations; followed by the 40–49-
year-old group, with 3.9 cases/1000 examinations; the fre-
quency was lowest in the 50–59-year-old group, with 3.4
cases/1000 examinations (Table 3). The frequency of can-
cer was significantly higher in women aged 60–69 years
compared with the other two groups; 50–59 years (p <
0.001) and 40–49 years (p < 0.001); but no significant dif-
ference was found between women aged 40–49 years and
50–59 years (p = 0.164).
Based on the Classification of Malignant Tumors (TNM)
of the International Union Against Cancer, 43.4% of tu-
mors were diagnosed as early development stage tumors
(CS 0 and CS I). This represented 48.6% of tumors
detected in the FU and 39.1% of tumors detected in the
MU. Advanced stage tumors (CS III and CS IV) ac-
counted for 15.8% of all cases, and represented 14.3% of
those detected in the FU and 17% of those detected in the
MU (Table 2).
Discussion
Managers in public health authorities must constantly
encourage adherence to breast cancer screening pro-
grams to optimize early detection and reduce the asso-
ciated morbidity and mortality at the population level
[18,19]. Participation is naturally a strong prerequisite
of the program’s impact; the lack of adherence to the
programs can be attributed to a number of factors, inclu-
ding long distances to travel for access to medical facilities
[20-22], unavailability of services, low socioeconomic
status [21,22], etc. Worldwide, participation in a first
round of a breast cancer screening program varies widely,
with a range of 10.6% to 54.2% in Canada [12], 34% in
Luxembourg [23], 46% in Switzerland [22], 48% in France
[24], 47% to 78.1% in Croatia [25], 70.6% in Stockholm
[26], 71% in Copenhagen [27], 73% in England [28], 53%
Table 1 Characteristics of program participants
Variable Category n (%)
Previous MMG Yes 10,404 (57.9%)
No 7,560 (42.1%)
Screening unit Mobile Unit 10,521 (58.6%)
Fixed Unit 7,443 (41.4%)
Age group (years) 40–49 8,659 (48.2%)
50–59 6,179 (34.4%)
60–69 3,126 (17.4%)
Strategies for invitation Community health agents 8,406 (46.8%)
Physicians 4,861 (27.1%)
Radio announcements 2,219 (12.4%)
Conversations with friends 1,026 (5.7%)
Other reasons 1,452 (8.1%)
Total 17,964 (100.0%)
Abbreviation: MMG = mammography.
Table 2 Characteristics of breast cancers
Variable Category n (%)
Screening unit Mobile Unit 41 (53.9%)
Fixed Unit 35 (46.1%)
Histological type Invasive ductal carcinoma 55 (72.4%)
Invasive lobular carcinoma 13 (17.1%)
Ductal carcinoma in situ 8 (10.5%)
Clinical Stage 0-I 33 (43.4%)
II 31 (40.8%)
III-IV 12 (15.8%)
Total 76 (100%)
Table 3 Cases of cancer according to the number of
mammographies by age
Age group
(years)
Mammography
examinations
Cancer
cases
Cases/1,000
MMG
40–49 8,666 (48.2%) 34 (44.7%) 3.9
50–59 6,173 (34.4%) 21 (27.6%) 3.4
60–69 3,125 (17.4%) 21 (27.6%) 6.7
Total 17,964 (100%) 76 (100%) 4.2
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to 87% in Spain [29], 75.7% in the Netherlands [30] and
85% to 95% in Finland [13]. The participation rate of
women in our program was 33.1% during the first 2-year
round. This was lower than the rates reported in some
nations [17,31], but it was similar to rates reported for
other trials in the initial phases [12,23]. Non-participation
in the screening program was partly due to the fact that
some of the population had received mammography
examinations outside the program. Those women opted
to obtain private health insurance, rather than use public
national health services [32-34]. The lack of systematic
data available on the performance of mammography
screening has given rise to deep concern about the actual
attendance in screening programs [12,23].
In some European countries, women are identified
from the national population registry with a unique per-
sonal identification number, and letters of invitation are
sent efficiently with an appointment time. Thus, a high at-
tendance rate is guaranteed [13,26,27]. In Luxembourg,
the attendance rate in opportunistic screening programs
was reduced by adopting a policy of exclusively reimbur-
sing women for mammographs performed in the context
of an organized screening program [23]. However, this
strategy was not feasible in Brazil, where the constitution
guarantees all women the right to receive a mammog-
raphy free of charge in the public health system.
In Canada, women in the target age range had access to
mammography by participating in breast cancer screening
programs organized provincially or territorially. The par-
ticipation rate in seven of these provinces ranged from
10.6% to 54.2%, and five provinces had rates below 30%
[12]. In one Canadian survey, 53.7% of women aged
50–69 years self-reported that they had had a screening
mammogram within the previous 2 years; it was estimated
that 21% of those women were screened through an orga-
nized program. The low attendance in organized scree-
ning programs may be attributed to: (1) a low capacity for
mammography screening; (2) difficulty in shifting from
preventive health care practices and opportunistic scree-
ning to organized, systematic screening; (3) an inability, in
some jurisdictions, to access population information that
would facilitate inviting women in the target age range;
and (4) a lack of understanding or confidence in the po-
tential benefits of regular mammography screening among
women and physicians [12].
In this study, there were several possible explanations
for the low participation rate, including: (1) lack of a
national registry that stored information on targeted wo-
men. The absence of this information may have ham-
pered the ability to identify and access women targeted
to participate in the program; (2) approximately 25% of
the regional population covered by the breast cancer
prevention program had private health insurance, which
facilitated access to mammography outside our program;
(3) lack of experience in community intervention. This
was the first breast cancer screening program with mam-
mography; (5) low adherence of physicians that worked in
the municipalities; (6) lack of organization in the Brazilian
Health System to accommodate breast cancer screening,
and (7) inherent cultural concerns that the examinations
may identify cancer and require a referral to and/or exam-
ination in a hospital, where they would be exposed to sick
people. In the initial stages of this project, the Barretos
Cancer Hospital offered mammography and confirmatory
exams in the same building that provided the treatments,
including chemotherapy, radiotherapy, and surgery. This
created a problem due to the close association with con-
firmed cancer. The problem was resolved in December
2009, with the inauguration of the Barretos Cancer
Hospital´s Prevention Department building, where only
apparently healthy women were examined.
The number of participants in each age group in the
Barretos Cancer Hospital screening program reflected
the sizes of the age groups in the eligible population of
the Barretos region. The 40 to 49-year-old groups com-
prised 48.2% of the screened population and 45.2% of
the eligible population; the 50 to 59-year-old groups
comprised 34.4% of the screened population and 31.9%
of the eligible population; and the 60 to 69-year-old
groups comprised 17.4% of the screened population and
22.8% of the eligible population. The results from mam-
mogram examinations performed in women aged 40 to
49 years were not significantly different from those per-
formed in women aged 50 to 59. Despite the low number
of cases, the results suggested that it would be prudent
to initiate mammographic screening in relatively young
women. This would optimize the detection of early tu-
mors, despite differences in causality and ethnicity among
different regions in Brazil.
This study ratified the large demand for MU exami-
nations; our results corroborated the assumption that
the MU was an important tool for facilitating access to
mammography [35]. The MU was a critical part of the
strategy to overcome obstacles represented by remote
areas, poor resources, and/or difficulty in accessing the
public health system [35]. A national survey of mam-
mography facilities in the US revealed that 2.4% of mam-
mograms were performed in a MU, but the number of
units assessed was low [36]. On the other hand, the
Netherlands had 66 units, mostly mobile units, with an
annual national coverage of 80% [37]; this provided evi-
dence for the importance and feasibility of MUs.
The MU has been used in developed countries to ser-
vice population groups with restrictions that prevented
participation in screening for breast cancer. These groups
generally comprised women with low incomes, low levels
of education, and older age, in addition to other limita-
tions, such as residing in a rural area [38-41]. The MU
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approach has also been used to aid in organized scree-
nings. In small counties, the MU was assumed to provide
easy access to a mammogram examination for women
who lived at a distance from cities with appropriate re-
sources for breast examinations [42]. Our findings firmly
supported this assumption. We found that 10 521 (58.6%)
women sought mammograms in the MU, compared with
7443 (41.4%) women that were examined in the FU.
Radiologists in the MU conducted a daily average of
26.3 examinations, with an occupancy rate of 65.7%. In
contrast, the FU showed an occupancy rate of 15.5%,
with an average of 18.6 examinations per day. Clearly,
the units were not operating at full capacity, but the MU
in fact answered an underlying need of the population
resident in the rural areas more than the FU did with re-
spect to the urban population, which was already par-
tially covered by opportunistic screening outside the
program. This highlighted the urgency of implementing
more comprehensive communication between the popu-
lation and public health system to optimize the potential
benefits of mammographic screening.
Women were invited to participate in the screening pro-
gram through various sources, including the media, press,
radio, letters, lectures, etc. Some of these methods were
previously used in developed countries, such as the invita-
tion letter, which resulted in a participation rate of 85%
[43]. Other programs have combined this strategy with
media campaigns; these approaches achieved success rates
greater than 70% [44]. In our study, the best strategy
for promoting participation was an individual suggestion
given particularly by community healthcare workers
(46.8%). The next most successful strategy was the recom-
mendation from a physician; this persuaded 27.0% of wo-
men to have a mammogram. This finding is very important,
because a significant percentage of women received in-
formation from their doctors.
In the present study, the recall rate of screening was
9.4%, slightly above the 7% recall rate that is most com-
monly recommended in population-based programs as
the upper acceptable limit for the first screening round
according to the European Guidelines for Breast Cancer
Screening [45]. The Breast Cancer Surveillance Consortium
of the U.S. National Cancer Institute, the national breast
cancer early detection program of the U.S. Centers for
Disease Control and Prevention, and the UK National
Health Service Breast Screening Program had recall
rates of 13.1%, 11.2%, and 7.4%, respectively, for the first
round of screening [46]. The positive predictive value for
biopsies was low (16%) compared with the indication
from BI-RADS, which ranged from 25% to 40%; this
indicated that many patients referred for biopsy had no
lesions. This suggested that, although the radiologists
had proven experience performing diagnostic mammo-
graphy, apparently, they did not feel comfortable assessing
and diagnosing patients with minimal mammographic
alterations. This may have been because they had no spe-
cific training in breast radiology; in addition, we used
stringent quality assurance and quality control guidelines
[47]. The issue of professional training of medical and
technical personnel in the assessment units of the scree-
ning programs should be among the priorities for consi-
deration in further development of this project.
This program diagnosed 76 cases of breast cancer; the
detection rate was 4.23 cases per 1000 examinations. In
a large series from UK, a country with higher breast can-
cer incidence than Brazil, the detection rate ranged from
8.6 to 10.1 cases per 1000 examinations [46]. The absence
of a population-based registry in this region of Brazil pre-
vents the determination of breast cancer prevalence in
these women for comparison. However, estimates of the
INCA show a prevalence of 68.9 cases for 100,000 women
in the State of Sao Paulo [48].
One primary objective of screening programs is to iden-
tify early stage cancer. We found that 43.4% of tumors
were in the early stages of development (EC 0 and EC I).
Of note, both symptomatic and asymptomatic women
were included in this class, because symptoms were not
known initially. This frequency was higher than the
20% reported in the state of Sao Paulo, according to
the Oncocentro Foundation of São Paulo [49], and higher
than the 14.5% observed in the Barretos region, according
to the Cancer Registry of Barretos Cancer Hospital in the
period prior to the start of the present screening program.
Conversely, in patients with more advanced breast cancer,
we observed significant improvements over previous
observations, as a result of early screening. We found that
tumors in advanced stages (CS III and CS IV) accounted
for 15.8% of cancers detected in both units, compared
with 39.0% from the state of São Paulo [49] and 40.5%
from previous reports of the Barretos region. These fin-
dings are important, because they demonstrate the effi-
ciency and relevance of this screening program and they
indicate the actual status of breast cancer in Brazil. This
approach can lead to new screening programs, or it can
be used to improve existing programs, even in the first
round. Thus, our findings confirmed, in part, the impor-
tance of implementing an organized screening program
for the prevention of breast cancer.
Although we obtained accurate data and successfully
implemented a system of early detection for breast can-
cer, the major methodological limitation of this study
was that we failed to separate symptomatic from asymp-
tomatic women. This initiative was consistent with the
philosophy of the Barretos Cancer Hospital, which in-
cluded the Department of Prevention. Currently, there is
a registry that distinguishes symptomatic from asymp-
tomatic women, but both groups continue to be served
by the screening program. In addition, there was a high
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demand for mammography in the region, which was con-
firmed by the high number of referrals from doctors for
early detection screening. Consequently, the overall prob-
lem was large, due to the lack of a health policy priority
system for mammographic screening. The early detec-
tion program described here was functional and provi-
ded acceptable results. The MU approach offers potential
for progressive improvement in early detection of breast
cancer.
Conclusions
Our findings support the notion that it would be advisable
to plan and set up a comprehensive, population-based
breast screening project in the 40–69 age group in our re-
gion. This should include the implementation of a mo-
nitoring system based on the complete registration of
all breast cancer cases in the target population, both
symptomatic and asymptomatic, diagnosed both within
the screening units and through other diagnostic facilities.
Also, high quality, specific training should be required for
all professionals involved in the execution, interpretation
and diagnostic work-up of screening mammographs.
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